Pfizer Inc.

Latest Stories

Laboratory technicians test a blood sample for HIV infection at the Reproductive Health and HIV Institute (RHI) in Johannesburg, Thursday, Nov. 26 2020. The successful trials of a new injectable drug that needs to be taken every eight weeks to prevent HIV infection is being lauded on World AIDS Day as a turning point for the fight against a global health threat that's been eclipsed by the coronavirus pandemic. (AP Photo/Denis Farrell)

On World AIDS Day, South Africa finds hope in new treatment

By MOGOMOTSI MAGOME - Associated Press

A man has his temperature checked prior to entering a store in Montreal, Sunday, Nov. 22, 2020, as the COVID-19 pandemic continues in Canada and around the world. (Graham Hughes/The Canadian Press via AP)

Virus News: G-20 leaders vow to make vaccines available

By The Associated Press - Associated Press

FILE - In this Nov. 9, 2020, file photo, pedestrians walk past Pfizer world headquarters in New York. Pfizer announced Wednesday, Nov. 18, 2020, more results in its ongoing coronavirus vaccine study that suggest the shots are 95% effective a month after the first dose. (AP Photo/Bebeto Matthews, File)

Pfizer seeking emergency use of its COVID-19 vaccine in U.S.

By Lauran Neergaard - Associated Press

FILE - In this March 16, 2020, file photo, Neal Browning receives a shot in the first-stage safety study of a potential vaccine for COVID-19 at the Kaiser Permanente Washington Health Research Institute in Seattle. Moderna Inc., said Monday, Nov. 16, its COVID-19 vaccine is proving to be highly effective in a major trial. (AP Photo/Ted S. Warren, File)

Volunteers still needed to test variety of COVID-19 vaccines

By LAURAN NEERGAARD - Associated Press

President Donald Trump speaks in the Rose Garden of the White House, Friday, Nov. 13, 2020, in Washington. (AP Photo/Evan Vucci)

AP FACT CHECK: Trump distorts on vaccine, state distribution

By HOPE YEN and LAURAN NEERGAARD and CANDICE CHOI - Associated Press

N.C. health system aims to be early vaccine distributor

Associated Press

FILE - In this June 5, 2019, file photo, Dr. Randall Williams, Director of the Missouri Department of Health and Senior Services, speaks with reporters in St. Louis. Williams told a House committee on Tuesday, Nov. 10, 2020, that he expects a COVID-19 vaccine to be available for a limited number of people by mid-December. Pfizer on Monday, Nov. 9 announced it has developed a vaccine that has proven 90% effective in early testing. (Robert Cohen/St. Louis Post-Dispatch via AP, File)

Missouri health director hopeful vaccine is coming soon

By DAVID A. LIEB and JIM SALTER - Associated Press

President Donald Trump gives two thumbs up to supporters as he departs after playing golf at the Trump National Golf Club in Sterling Va., Sunday Nov. 8, 2020. (AP Photo/Steve Helber)

AP FACT CHECK: Trump’s claims on vaccine, election are wrong

By HOPE YEN and LAURAN NEERGAARD and LINDA A. JOHNSON - Associated Press

Study finds long-acting shot helps women avoid HIV infection

By MARILYNN MARCHIONE - Associated Press

An ad for COVID-19 testing reflects on glass at a bus stop, as pedestrians walk past Pfizer world headquarters in New York on Monday Nov. 9, 2020. Pfizer says an early peek at its vaccine data suggests the shots may be 90% effective at preventing COVID-19, but it doesn't mean a vaccine is imminent. (AP Photo/Bebeto Matthews)

Key events in development of Pfizer’s COVID-19 vaccine

By AP Medical Writer - Associated Press

Pedestrians walk past Pfizer world headquarters in New York on Monday Nov. 9, 2020. Pfizer says an early peek at its vaccine data suggests the shots may be 90% effective at preventing COVID-19, but it doesn't mean a vaccine is imminent. (AP Photo/Bebeto Matthews)

Testing timeline: What’s ahead for COVID-19 vaccines

By LAURAN NEERGAARD - Associated Press

In this photo provided by Cincinnati Children’s Hospital Medical Center, clinical research coordinator Tammy Lewis-McCauley administers an injection to Katelyn Evans, a trial participant, as part of the hospital’s clinical trial of Pfizer's COVID-19 vaccine at Cincinnati Children’s Hospital Medical Center on Wednesday, Oct. 14, 2020. (Cincinnati Children’s Hospital Medical Center via AP)

Pfizer says early data signals COVID-19 vaccine is effective

By Linda A. Johnson and Lauran Neergaard - Associated Press

FILE - In this Feb. 26, 2019 file photo, Albert Bourla, chief executive officer of Pfizer, prepares to testify before the Senate Finance Committee hearing on drug prices, on Capitol Hill in Washington. Pfizer Inc.'s CEO says it can't seek emergency authorization of its COVID-19 vaccine before the third week of November — and that's if everything goes well. The announcement on Friday, Oct. 16, 2020, by Bourla reflects estimates from leading scientists that its unlikely data would start to emerge until November or December showing any of the leading vaccine candidates work. (AP Photo/Pablo Martinez Monsivais, File)

Pfizer: Mid-November earliest it can seek virus vaccine OK

Associated Press

FILE - This Aug. 2, 2018, file photo shows the U.S. Food and Drug Administration building behind FDA logos at a bus stop on the agency's campus in Silver Spring, Md. Investors are driving shares of drug developer BioMarin down by a third after U.S. regulators rejected its potentially game-changing gene therapy for hemophilia A patients. The FDA's rejection late Tuesday, Aug. 18, 2020, means BioMarin will have to complete an ongoing late-stage patient study. (AP Photo/Jacquelyn Martin, File)

FDA blocks much-anticipated BioMarin hemophilia gene therapy

By LINDA A. JOHNSON - Associated Press

A passers-by, right, walks past a storefront window, Tuesday, July 28, 2020, in Boston. (AP Photo/Steven Senne)

Pfizer executive targets end of year for COVID-19 vaccine

Associated Press

Connecticut Gov. Ned Lamont speaks at a press conference at Pfizer Groton on the companies research to develop a vaccine for COVID-19, Wednesday, July 22, 2020, in Groton, Conn. The federal government has agreed to pay nearly $2 billion for 100 million doses of a potential COVID-19 vaccine being developed by the U.S. drugmaker and its German partner BioNTech. (AP Photo/Stew Milne)

Pandemic hurts sales, profit for Pfizer amid restructuring

By LINDA A. JOHNSON - Associated Press

John Burkhardt, left, senior vice president of drug safety R&amp;D and head of the Pfizer Groton site speaks at a press conference at Pfizer Groton on the companies research to develop a vaccine for COVID-19, as Connecticut Gov. Ned Lamont stands by to answer questions Wednesday, July 22, 2020, in Groton, Conn. The federal government has agreed to pay nearly $2 billion for 100 million doses of a potential COVID-19 vaccine being developed by the U.S. drugmaker and its German partner BioNTech. (AP Photo/Stew Milne)

Pfizer’s CT scientists playing key role in vaccine effort

By SUSAN HAIGH - Associated Press

In this March 16, 2020, file photo, a subject receives a shot in the first-stage safety study clinical trial of a potential vaccine by Moderna for COVID-19, the disease caused by the new coronavirus, at the Kaiser Permanente Washington Health Research Institute in Seattle. According to results released on Tuesday, July 14, 2020, early-stage testing showed the first COVID-19 vaccine tested in the U.S. revved up people’s immune systems the way scientists had hoped. The vaccine is made by the National Institutes of Health and Moderna Inc. (AP Photo/Ted S. Warren, File)

First COVID-19 vaccine tested in US poised for final testing

By Lauran Neergaard - Associated Press

Pfizer 1Q sales and profit down, but it maintains 2020 views

By LINDA A. JOHNSON - Associated Press

Pfizer posts 4Q loss, misses Street views, on lower revenue

By LINDA A. JOHNSON - Associated Press